DS

David Simmonds

Arovella Therapeutics Limited | Non-Executive Director
Mr Simmonds was a senior audit partner with Ernst & Young. David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. As an audit partner, David was involved in several high-profile businesses including Ramsay Health Care Ltd, John Fairfax Holdings and Commonwealth Bank of Australia and also was audit partner for the Australian operations of the leading US technology companies Hewlett Packard, Sun Microsystems and Oracle. David was a member of the Board and chaired the Audit, Risk and Finance Committee of MS Research Australia, the largest national not-for-profit body dedicated to funding and coordinating multiple sclerosis research in Australia.

Company and Role

Company
Title
Tenure
Since
ALA
Arovella Therapeutics Limited
  • Non-Executive Director
5yrs, 3mthMar 2019

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ALA
Arovella Therapeutics Limited
31/08/23513,157N/A1,600,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ALA
Arovella Therapeutics Limited
15/12/22
Issued
1,600,000$0.025$40,000Director remuneration
ALA
Arovella Therapeutics Limited
16/03/22
Issued
263,157$0.038$9,999Placement
ALA
Arovella Therapeutics Limited
05/11/20
Buy
250,000$0.040$10,000On-market trade